Varicella Vaccines Market – Global Outlook & Forecast 2021-2031

Varicella Vaccines Market – Global Outlook & Forecast 2021-2031

Varicella Vaccines Market Introduction

Varicella also known as chicken pox, is highly contagious, and affects mainly children of age 2‒8 years. It is caused by the varicella zoster virus (VZV), the virus which also causes shingles (herpes zoster). Symptoms of varicella includes characteristic skin rash that forms small, itchy blisters, which eventually scab over. Other symptoms may include fever, tiredness, and headaches. It mainly starts on the chest, back, face and then spreads to the rest of the body. Immunization is the most effective way for prevention of varicella.

Market - Headwinds & Tailwinds

The global varicella vaccine market is mainly driven by rising awareness for immunization, growing number of new born babies globally and various initiatives for making vaccine available to low- and middle-income countries. Increasing government support for vaccine development is also playing a pivotal role in contributing to growth of the market globally. However, high cost of vaccine development and religious beliefs among certain communities against vaccination are likely to restrain the market growth to a certain extent. 

Varicella Vaccines Market Report

 

Market Segmentation & Insights

The global varicella vaccine market has been analyzed from three perspectives: Patient Type, Product Type and Region. 

Varicella Vaccine Market by Patient Type

Based on patient type, the market has been segmented into pediatric patients and adult patients. The pediatric patients segment accounted for the largest share in the market owing to high vulnerability of varicella infection in children. Inclusion of varicella vaccine in childhood immunization programme by various government agencies around the world can also be attributed to the growth of the market.

Varicella Vaccine Market by Product Type

Based on product type, the varicella vaccine market has been segmented into monovalent varicella vaccine and combination varicella vaccine. Monovalent varicella vaccine segment holds the largest share in the market. The growth of the segment can mainly be attributed to availability of large number of monovalent varicella vaccines in market as compared to combination varicella vaccines. At present, there are only two combination varicella vaccines licensed in the market, namely, ProQuad and Priorix-Tetra. Whereas, there are more than eight monovalent varicella vaccine licensed in the market, namely, VARIVAX, Varilrix, VARICELLA VACCINE LIVE ATTENUATED "BIKEN”, Varicella Vaccine-GCC inj., ZUVICELLA, SKY Varicella, among others.

Varicella Vaccine Market by Region

Based on region, the global varicella vaccine market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World (ROW). North America dominated the varicella vaccine market, followed by Asia Pacific. The large share of North America in the global market can largely be attributed to the presence of key prominent players, outbreak of chicken pox, and increasing government initiatives for vaccination.

Competitive Landscape

The varicella vaccine market is marked by presence of prominent players such as GlaxoSmithKline plc., Merck & Co., Inc., Sinovac Biotech Ltd., BIKEN, Changchun BCHT Biotechnology Co., Ltd, Green Cross Corp., Zuventus HealthCare Ltd., BIO-MED, SK bioscience., among others.

Snapshot: Industry Developments 

• In Dec 2019, Sinovac Biotech Ltd. announced that the China National Medical Products Administration (NMPA) has approved and issued a product license for the company’s varicella vaccine to prevent the varicella-zoster virus in children from 1 to 12 years of age

• In Dec 2019, SK bioscience’s Sky varicella received pre-qualification (PQ) certification from the World Health Organization (WHO). This certification makes company eligible to participate in international bids organized by U.N. agencies, such as UNICEF and Pan American Health Organization (PAHO)

Key Insights Captured in the Report

• Quantitative (market size and forecasts) and qualitative insights of the market across years - historical years, current year and forecasted years 

• Deep-rooted insights on headwinds, tailwinds and opportunities prevailing in the market

• Quantitative (market size and forecasts) and qualitative insights at segment and sub-segment level

• Comprehensive quantitative (market size and forecasts) and qualitative insights on geographic, regional and country level markets

• Granular insights on the competitive landscape prevailing in the market

• Competitive mapping of strategic developments 

Scope of the Varicella Vaccines Market Report:

Report Metrics Details
Market Size Period 2018-2031
Base Year 2020
Forecast Period 2021-2031
Market Segments Asessment of Varicella Vaccines Market By:
• Patient Type
• Product
• Region
Geographic Scope North America
◦ U.S.
◦ Canada
Europe
◦ Germany
◦ UK
◦ France
◦ Rest of Europe (RoE)
Asia Pacific
◦ China
◦ Japan
◦ India
◦ Rest of Asia Pacific (RoAPAC)
Rest of the World
◦ Latin America
◦ Middle East & Africa
Companies Covered GlaxoSmithKline plc., Merck & Co., Inc., Sinovac Biotech Ltd., BIKEN, Changchun BCHT Biotechnology Co., Ltd, Green Cross Corp., Zuventus HealthCare Ltd., BIO-MED, SK bioscience., among others.

1 RESEARCH ENVELOPE

1.1 Market Classification

1.2 Scope of the Study

1.2.1 Timeline Considered for Market Study

· Historic Years – 2018 & 2019

· Base Year – 2020

· Projected Years – 2021 to 2031

1.3 Currency Used in the Report

2 RESEARCH METHODOLOGY

2.1 Research Approach

2.2 Data Collection Methodology

2.3 Data Sources

2.3.1 Secondary Sources

2.3.2 Primary Sources

2.4 Market Crackdown Methodology

2.4.1 Bottom-Up Approach

2.4.2 Top-Down Approach

2.5 Data Forecasting Model

2.6 Limitations and Assumptions for Study

3 HEADWINDS & TAILWINDS ASSESSMENT

4 MARKET OPPORTUNITIES ASSESSMENT

5 PREMIUM INSIGHTS

5.1 Key Market Trends

5.2 Key Players & Their Competitive Positioning (2020)

5.3 COVID-19 Impact Assessment

5.4 Pipeline Assessment

6 GLOBAL VARICELLA VACCINE MARKET - ANALYSIS & FORECAST, BY PATIENT TYPE

6.1 Pediatric Patients

6.2 Adult Patients

7 GLOBAL VARICELLA VACCINE MARKET - ANALYSIS & FORECAST, BY PRODUCT TYPE

7.1 Monovalent Varicella Vaccine

7.2 Combination Varicella Vaccine

8 GLOBAL VARICELLA VACCINE MARKET - ANALYSIS & FORECAST, BY REGION

8.1 North America Varicella Vaccine Market

8.1.1 North America Varicella Vaccine Market, By Country

8.1.1.1 U.S.

8.1.1.2 Canada

8.1.2 North America Varicella Vaccine Market, By Patient Type

8.1.3 North America Varicella Vaccine Market, By Product Type

8.2 Europe Varicella Vaccine Market

8.2.1 Europe Varicella Vaccine Market, By Country/Region

8.2.1.1 Germany

8.2.1.2 U.K

8.2.1.3 France

8.2.1.4 Rest of Europe (ROE)

8.2.2 Europe Varicella Vaccine Market, By Patient Type

8.2.3 Europe Varicella Vaccine Market, By Product Type

8.3 Asia Pacific Varicella Vaccine Market

8.3.1 Asia Pacific Varicella Vaccine Market, By Country/Region

8.3.1.1 China

8.3.1.2 Japan

8.3.1.3 India

8.3.1.4 Rest of Asia Pacific (RoAPAC)

8.3.2 Asia Pacific Varicella Vaccine Market, By Patient Type

8.3.3 Asia Pacific Varicella Vaccine Market, By Product Type

8.4 Rest of the World (RoW) Varicella Vaccine Market

8.4.1 Rest of the World Varicella Vaccine Market, By Region

8.4.1.1 Latin America

8.4.1.2 Middle East & Africa

8.4.2 Rest of The World Varicella Vaccine Market, By Patient Type

8.4.3 Rest of The World Varicella Vaccine Market, By Product Type

9 COMPANY PROFILES

9.1 GlaxoSmithKline plc.

9.1.1 Business Overview

9.1.2 Financial Metrics*

9.1.3 Product Portfolio

9.1.4 Key Developments

9.2 Merck & Co., Inc.

9.3 Sinovac Biotech Ltd.

9.4 BIKEN

9.5 Changchun BCHT Biotechnology Co., Ltd

9.6 Green Cross Corp.

9.7 Zuventus HealthCare Ltd.

9.8 BIO-MED

9.9 SK bioscience.

9.10 Other Prominent Players

*Insights on financial metrics is subject to availability of information in the public domain

Download Report Sample PDF

Specific Requirement Form

Solitary

  • The solitary license authorizes only one individual to use the report
  • A PDF version of the report will be delivered that can be viewed on only one authorized system
  • Free analyst support for 20 hours is extended as a value-added service
  • Buyers need to share the ‘Name and Email ID of the authorized user
  • Imitation, distribution as well as quoting of the contents of the report is prohibited without the prior permission of Clairvoyance Research

$4850

Compound

  • Compound license authorizes only 5 individuals to use the report
  •  A PDF/Printable version of report will be delivered that can be viewed on only 5 authorized systems
  • Free analyst support for 40 hours is extended as a value-added service
  • Buyers need to share ‘Names and Email IDs’ of the authorized users 
  • Imitation, distribution as well as quoting of the contents of the report is prohibited without the prior permission of Clairvoyance Research

$5850

Corporate

  • Corporate license authorizes unlimited individuals to use the report
  • A PDF/Printable version of report will be delivered that can be viewed on unlimited systems
  • Free analyst support for 80 hours is extended as a value-added service
  • This license type allows extraction of top-level market data tables in ‘Excel’ format and also permits the buyer to quote the contents of the report published by Clairvoyance Research

$6850

Data Pack

  • Data Pack’ request provides customers all ‘Quantitative Insights’ with respect to a particular market in an excel-based dashboard format

$2250

Purchase Options

Solitary $4850

Compound $5850

Corporate $6850

Data Pack $2250

  • The solitary license authorizes only one individual to use the report
  • A PDF version of the report will be delivered that can be viewed on only one authorized system
  • Free analyst support for 20 hours is extended as a value-added service
  • Buyers need to share the ‘Name and Email ID of the authorized user
  • Imitation, distribution as well as quoting of the contents of the report is prohibited without the prior permission of Clairvoyance Research

Popular Reports

Summer 3E,Purti Season,22 Buroshibtalla Main Road, Near Leela Petrol Pump, Kolkata, West Bengal-700038
+ 91 8761988338
10 AM to 10 PM
info@clairvoyanceresearch.com
Support line
TOP